Improved survival in multiple myeloma and the impact of novel therapies.
about
Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trialsFirst-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studiesThree-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myelomaPrevalence of monoclonal gammopathy of undetermined significance: a systematic reviewBlockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myelomaAdvances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myelomaElotuzumab: the first approved monoclonal antibody for multiple myeloma treatmentDaratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myelomaNovel agents in the treatment of multiple myeloma: a review about the futureClinical use and applications of histone deacetylase inhibitors in multiple myelomaMultiple myeloma in the very elderly patient: challenges and solutionsMicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow MicroenvironmentEfficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-AnalysisImmunotherapy in Multiple Myeloma Using Cancer-Testis AntigensRecent advances in the field of anti-cancer immunotherapyTop Information Need Priorities of Older Adults Newly Diagnosed With Active MyelomaMonoclonal antibodies in the treatment of multiple myeloma: current status and future perspectivesNovel agents for multiple myeloma to overcome resistance in phase III clinical trialsPotential role of daratumumab in the treatment of multiple myelomaTreatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersImmunogenic targets for specific immunotherapy in multiple myelomaDefining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasiasSmoldering multiple myeloma requiring treatment: time for a new definition?Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementNew drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)European perspective on multiple myeloma treatment strategies in 2014Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomibImmunotherapy strategies for multiple myeloma: the present and the futureInnovative agents in multiple myelomaComparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trialsTargeted therapy for HM1.24 (CD317) on multiple myeloma cellsEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesVery late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myelomaDevelopment of Novel Immunotherapies for Multiple MyelomaThe Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveNew investigational drugs with single-agent activity in multiple myelomaMolecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple MyelomaRecent advances in multiple myeloma: a Korean perspectiveThe insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialNKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma
P2860
Q21133524-B7F1DF74-D7BC-4D1F-A96B-2A3065A0641BQ24197999-6D379449-0195-4123-A4D1-067C6EE4497CQ24202358-D412AB32-8797-4945-9BA6-EE719B7A8B7CQ24597406-3955C9CB-EC24-42B3-96A4-766CD6AD9611Q24598483-8562DA7B-1F4F-4C8B-917F-D699B4941831Q24619589-23DEB21F-2642-4B40-B1D4-AC0BC5A0C7B5Q26738944-E8ADBCBF-D69A-4520-90DC-75FDFBA9B5EBQ26745919-AF137E3B-0C5B-4654-B338-B6B3AE4D15D4Q26745924-A58FAD94-5924-4FB0-880C-DCD09BB06A1BQ26745930-C307E206-9629-470C-832E-6C153B3B6979Q26752991-F87E3534-EAE2-49E1-AE77-44E4C684F502Q26765477-AC7689BF-40EA-424C-BB74-4A29B44B513FQ26767418-7832350C-81B5-4822-A78B-4A2EB4BA8D0EQ26774913-EFAACE41-6102-4798-B5E4-6AA8F73B0385Q26775602-6165405E-7FA0-4277-99CB-52D1FDD990AFQ26785735-B72C2810-1029-41A9-9A4F-0B75744D73A1Q26799104-5F760E51-D745-49DF-85CC-45D3B2CF593EQ26822754-C788FC20-A0E7-430F-A105-69C2E6B31928Q26824157-F061E27E-3F44-477D-8717-2756AE141191Q26851202-315706A6-2720-40DC-8BB3-CDDBD4F46733Q26859007-B9470297-7CF3-4C0C-88BF-E102E4023CB5Q26861037-4A84B9FC-17BE-43BE-997B-072C0AAA16A7Q26996579-764C68C1-A4F6-4759-99BE-265F0DBD025AQ26998884-B70A6CB1-F0F7-42AA-A5BA-E606DA749ED4Q27004421-50964F6C-646E-464E-AFA5-005BE5FAA6B6Q27005966-8B7543E4-E20B-49A8-879E-527EF04FD503Q27014143-6345E6D9-3206-4CD8-8F21-12BF3BA15CF2Q27021939-7DC5B9E0-352B-401C-B086-3EA0AF571B9BQ27022493-A12175BF-7E5F-4B50-9B18-1FFB94C2AC6AQ27024932-EFE7C840-05BB-403D-A1A2-7665D525E496Q27026161-79B74017-09DA-40F3-B7B9-63C58AC32BF2Q27026478-924E2A82-723A-4B13-944A-120F3B78457DQ27316139-B7E65A57-D26A-463E-A3C0-27B11F190CCCQ28066890-8A0318B2-C80D-4507-974A-037F367CF92DQ28069789-A2FF48A7-34FE-4B8F-A875-7E4582852B25Q28071551-2423B08F-DDBE-448C-96EC-65BB0022E9B4Q28074490-3A0362AF-A8DF-4B0C-935E-531613F9433DQ28074521-6A6FBE7E-14A1-480D-AFBD-D29A4C06C2C7Q28075927-1EA53F49-2FBC-4399-BD26-F2A47321BE85Q28080823-2128348F-3841-4880-B2C3-E9C094E28296
P2860
Improved survival in multiple myeloma and the impact of novel therapies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Improved survival in multiple myeloma and the impact of novel therapies.
@ast
Improved survival in multiple myeloma and the impact of novel therapies.
@en
type
label
Improved survival in multiple myeloma and the impact of novel therapies.
@ast
Improved survival in multiple myeloma and the impact of novel therapies.
@en
prefLabel
Improved survival in multiple myeloma and the impact of novel therapies.
@ast
Improved survival in multiple myeloma and the impact of novel therapies.
@en
P2093
P2860
P50
P1433
P1476
Improved survival in multiple myeloma and the impact of novel therapies.
@en
P2093
Francis K Buadi
John A Lust
Philip R Greipp
Shaji K Kumar
P2860
P304
P356
10.1182/BLOOD-2007-10-116129
P407
P50
P577
2007-11-01T00:00:00Z